The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going

Digestion

Volumn 93, Issue 2, 2016, Pages 149-159

  Khoury, Tawfik ^a   Ayman, Abu Rmeileh ^a   Cohen, Jonah ^c   Daher, Saleh ^b   Shmuel, Chen ^a   Mizrahi, Meir ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Department of Medicine ^*  (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulation; Cirrhosis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

ANTICOAGULANT THERAPY; BLEEDING; HEMOSTASIS; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VENOUS THROMBOEMBOLISM; BLOOD COAGULATION DISORDERS; CHEMICALLY INDUCED; COMPLICATION; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; PATIENT SELECTION;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIVER CIRRHOSIS; PATIENT SELECTION; VENOUS THROMBOEMBOLISM;

EID: 84954433646     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000442877     Document Type: Review

References (83)

1. Bechmann LP, Wichert M, Kröger K, Hilgard P: Dosing and monitoring of low-molecular-weight heparin in cirrhotic patients. Liver Int 2011;31:1064.
2. Tripodi A, Mannucci PM: The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147-156.
3. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005;41:553-558.
4. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, et al. An imbalance of pro-vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137:2105-2111.
5. O'Donnell J, Mumford AD, Manning RA, Laffan MA: Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol 2001;115:687-691.
6. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA: Factor VIII expression in liver disease. Thromb Haemost 2004;91:267-275.
7. Violi F, Ferro D, Basili S, Saliola M, Quintarelli C, Alessandri C, et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995;109:531-539.
8. Biagini MR, Tozzi A, Marcucci R, Paniccia R, Fedi S, Milani S, et al. Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis. World J Gastroenterol 2006;12:1607-1612.
9. Mangia A, Margaglione M, Cascavilla I, Gentile R, Cappucci G, Facciorusso D, et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol 1999;94:2983-2987.
10. Violi F, Ferro D, Basili S, D'Angelo A, Mazzola G, Quintarelli C, et al. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. BMJ 1994;309:239-240.
11. Kyrle PA, Eichinger S: Deep vein thrombosis. Lancet 2005;365:1163-1174.
12. Goldhaber SZ: Pulmonary embolism. Lancet 2004;363:1295-1305.
13. Heit JA: The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006;21:23-29.
14. Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010;103:947-953.
15. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
16. Huerta C, Johansson S, Wallander MA, García Rodríguez LA: Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007;167:935-943.
17. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. American College of Chest Physicians: Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):381S-453S.
18. Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, et al. Coagulation in Liver Disease Study Group: Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010;53:362-371.
19. Northup PG: Hypercoagulation in liver disease. Clin Liver Dis 2009;13:109-116.
20. Schrecengost JE, LeGallo RD, Boyd JC, Moons KG, Gonias SL, Rose CE Jr, et al. Comparison of diagnostic accuracies in outpatients and hospitalized patients of D-dimer testing for the evaluation of suspected pulmonary embolism. Clin Chem 2003;49:1483-1490.
21. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S: Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008;53:3012-3017.
22. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM: Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010;137:1145-1149.
23. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006;101:1524-1528; quiz 1680.
24. García-Fuster MJ, Abdilla N, Fabiá MJ, Fernández C, Oliver V, Forner MJ: [Venous thromboembolism and liver cirrhosis]. Rev Esp Enferm Dig 2008;100:259-262.
25. Anthony Lizarraga W, Dalia S, Reinert SE, Schiffman FJ: Venous thrombosis in patients with chronic liver disease. Blood Coagul Fibrinolysis 2010;21:431-435.
26. Wu H, Nguyen GC: Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol 2010;8:800-805.
27. Saleh T, Matta F, Alali F, Stein PD: Venous thromboembolism with chronic liver disease. Am J Med 2011;124:64-68.
28. Aldawood A, Arabi Y, Aljumah A, Alsaadi A, Rishu A, Aldorzi H, et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J 2011;9:1.
29. Ali M, Ananthakrishnan AN, McGinley EL, Saeian K: Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci 2011;56:2152-2159.
30. Zhang D, Hao J, Yang N: Protein C and D-dimer are related to portal vein thrombosis in patients with liver cirrhosis. J Gastroenterol Hepatol 2010;25:116-121.
31. Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009;51:682-689.
32. Lisman T, Porte RJ: Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010;116:878-885.
33. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364-2368.
34. Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005;41:603-608.
35. Senzolo M, Sartori MT, Lisman T: Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB (Oxford) 2009;11:459-464.
36. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54:691-697.
37. Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010;44:448-451.
38. Delgado MG, Seijo S, Yepes I, Achécar L, Catalina MV, García-Criado A, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10:776-783.
39. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143:1253-1260.e1-e4.
40. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS: Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther 2007;29:2395-2405.
41. Vivarelli M, Zanello M, Zanfi C, Cucchetti A, Ravaioli M, Del Gaudio M, et al. Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: is it necessary? World J Gastroenterol 2010;16:2146-2150.
42. Bechmann LP, Sichau M, Wichert M, Gerken G, Kröger K, Hilgard P: Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011;31:75-82.
43. Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG: Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014;34:26-32.
44. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011;139:69-79.
45. Garcia-Pagan JC, Valla DC: Portal vein thrombosis: a predictable milestone in cirrhosis? J Hepatol 2009;51:632-634.
46. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK: Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010;31:366-374.
47. Englesbe MJ, Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl 2010;16:83-90.
48. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 suppl):e152S-e184S.
49. Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001;120:490-497.
50. Lamps LW, Hunt CM, Green A, Gray GF Jr, Washington K: Alterations in colonic mucosal vessels in patients with cirrhosis and noncirrhotic portal hypertension. Hum Pathol 1998;29:527-535.
51. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G: Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995;21:1238-1247.
52. Wanless IR, Liu JJ, Butany J: Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995;21:1232-1237.
53. García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group: Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370-2379.
54. Senzolo M, M Sartori T, Rossetto V, Burra P, Cillo U, Boccagni P, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012;32:919-927.
55. Senzolo M, Rodriguez-Castro KI, Rossetto V, Radu C, Gavasso S, Carraro P, et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012;10:1823-1829.
56. Tripodi A, Baglin T, Robert A, Kitchen S, Lisman T, Trotter JF; Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis: Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease. J Thromb Haemost 2010;8:1410-1412.
57. Porte RJ, Lisman T, Tripodi A, Caldwell SH, Trotter JF; Coagulation in Liver Disease Study Group: The international normalized ratio (INR) in the MELD score: problems and solutions. Am J Transplant 2010;10:1349-1353.
58. Lisman T, van Leeuwen Y, Adelmeijer J, Pereboom IT, Haagsma EB, van den Berg AP, et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int 2008;28:1344-1351.
59. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell'Era A, Sei C, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007;46:520-527.
60. Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR: Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008;111:4471-4476.
61. Saner FH, Gieseler RK, Aklz H, Canbay A, Görlinger K: Delicate balance of bleeding and thrombosis in end-stage liver disease and liver transplantation. Digestion 2013;88:135-144.
62. Kelly DA, Tuddenham EG: Haemostatic problems in liver disease. Gut 1986;27:339-349.
63. Ewe K: Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981;26:388-393.
64. Dillon JF, Simpson KJ, Hayes PC: Liver biopsy bleeding time: an unpredictable event. J Gastroenterol Hepatol 1994;9:269-271.
65. Segal JB, Dzik WH; Transfusion Medicine/Hemostasis Clinical Trials Network: Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005;45:1413-1425.
66. Mallett SV, Cox DJ: Thrombelastography. Br J Anaesth 1992;69:307-313.
67. Spiess BD: Thromboelastography and cardiopulmonary bypass. Semin Thromb Hemost 1995;21(suppl 4):27-33.
68. Heresbach D, Bretagne JF, Raoul JL, Chaperon J, Piette C, Siproudhis L, et al. [Prognosis and prognostic factors of hemorrhage by rupture of varices in cirrhotic patients in the era of endoscopic sclerotherapy]. Gastroenterol Clin Biol 1991;15:838-844.
69. Planas R, Quer JC, Boix J, Canet J, Armengol M, Cabre E, et al. A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding. Hepatology 1994;20:370-375.
70. Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK: Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998;43:267-271.
71. Bedreli S, Sowa JP, Gerken G, Saner FH, Canbay A: Management of acute-on-chronic liver failure: rotational thromboelastometry may reduce substitution of coagulation factors in liver cirrhosis. Gut 2015;pii:gutjnl-2015-309922.
72. Viola F, Mauldin FW Jr, Lin-Schmidt X, Haverstick DM, Lawrence MB, Walker WF: A novel ultrasound-based method to evaluate hemostatic function of whole blood. Clin Chim Acta 2010;411:106-113.
73. Bauer KA: New anticoagulants: anti IIa vs anti Xa-is one better? J Thromb Thrombolysis 2006;21:67-72.
74. Schulman S, Crowther MA: How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012;119:3016-3023.
75. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
76. Graff J, Harder S: Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013;52:243-254.
77. Stangier J, Rathgen K, Stähle H, Mazur D: Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-268.
78. Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K: Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008;48:1411-1419.
79. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W: The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-399.
80. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-563.
81. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-1579.
82. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G: Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108:217-224.
83. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH; American College of Chest Physicians: Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 suppl):e195S-e226S.